Illumina Inc., Roche Holding AG - M&A Call

Illumina, Inc. (ILMN)

January 25, 2012 7:00 am ET


Daniel O'Day - Chief Executive Officer of Roche Molecular Diagnostics and President of Roche Molecular Diagnostics

Severin Schwan - Chief Executive officer

Alan Hippe - Chief Financial and IT Officer


Vincent Meunier - Exane BNP Paribas, Research Division

Gbola Amusa - UBS Investment Bank, Research Division

Keyur Parekh - Goldman Sachs Group Inc., Research Division

Luisa Hector - Crédit Suisse AG, Research Division

Sachin Jain - BofA Merrill Lynch, Research Division

Alexandra Hauber - JP Morgan Chase & Co, Research Division

Quintin J. Lai - Robert W. Baird & Co. Incorporated, Research Division

Michael Leacock - RBS Research

William R. Quirk - Piper Jaffray Companies, Research Division



Good morning or good afternoon. Welcome to the Roche conference call regarding the Illumina transaction. I'm Dino, the Chorus Call operator. [Operator Instructions] And the conference is being recorded. [Operator Instructions] The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Dr. Severin Schwan, CEO. Please go ahead, sir.

Severin Schwan

Welcome to everybody, and thank you for joining our call, which is going to last for about one hour. This is Severin speaking, and with me today, Alan Hippe, our Chief Financial Officer; and Dan O'Day, Chief Operating Officer of Roche Diagnostics.

Illumina is a great successful company, and we are excited to share with you the background of this planned acquisition. At the beginning, just let me shortly put this transaction into context. An important element of today's success of Roche Diagnostics is our breadth and depth of various key measuring technologies. They allow us to develop and market a broad range of diagnostic tests from molecular diagnostics to serum work area or tissue diagnostic testing. The completeness of our offering is important, both for our customers and Roche.

If you liked this article you might like

IPOs That Should Be on Your Radar

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement